Tivic Health Systems, Inc. (Nasdaq: TIVC), a development-stage immunotherapy company, announced its financial results for the year ended December 31, 2025, highlighting a significant strategic transformation into a focused immunotherapy company centered around its lead candidate, Entolimod. The company reported operating expenses of $7.9 million for 2025, up from $4.5 million in 2024, primarily due to the introduction of its biopharma business and increased headcount to support the development of Entolimod. The net loss before discontinued operations is expected to be between $7.9 million and $8.1 million, compared to $4.5 million in the previous year. Tivic has acquired exclusive global rights to Entolimod for acute radiation syndrome and is engaging with U.S. government agencies regarding potential funding and procurement. The company is also targeting the oncology supportive care market, focusing on neutropenia, with plans to advance this program into clinical trials later this year. The strategic transformation is expected to position Tivic for future growth and revenue generation, particularly through its wholly owned subsidiary, Velocity Bioworks, which aims to enhance manufacturing capabilities and reduce costs. The company will hold a conference call today at 1:30 PM PT to discuss these results and future outlook.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.